Animals immunized with native or recombinant envelope proteins from the human immunodeficiency virus (HIV, formerly referred to as human T-lymphotropic virus type III) human T-lymphotropic virus type IIIB and naturally HIV-infected men were assessed for neutralizing antibodies and cell-mediated immunity toward the virus. Immunization of rabbits or goats with the native external envelope glycoprotein gpl20 or with corresponding recombinant proteins elicited strictly type-speciflic neutralizing antibodies. A broad, group-specific cellular immune response to gpl20 and to three different HIV isolates was seen in goats immunized with the native gpl20 but not in animals immunized with the nonglycosylated recombinant envelope proteins. In HIV-infected people, no T-cell response was seen, even though their T-cell response toward other foreign antigens was intact. The results show type-and group-speciflic epitopes on gpl20, some of which may be of importance for the development of a vaccine against HIV infection.
In view of the continuing spread of the acquired immunodeficiency syndrome (AIDS) epidemic (1) , there is an urgent need for a vaccine against its etiologic agent, the retrovirus called human immunodeficiency virus [HIV, formerly referred to as human T-lymphotropic virus type III (HTLV-III)] (2). A logical candidate for such a vaccine is the external envelope glycoprotein gpl20 or corresponding recombinant or synthetic peptides. gpl20 contains conserved and variable regions (3, 4) and is mainly responsible for up to 30% of the variability observed between different HIV isolates. Neutralization assays with sera from HIV-infected individuals (5-7) or from immunized animals (8, 9) suggest that gpl20 contains epitopes that elicit antibodies capable of neutralizing HIV infection in vitro. As the group-specific neutralizing antibodies in infected individuals have only a limited effect on the progression of the disease (5) and as animal sera obtained by immunization with gpl20 or recombinant peptides are strictly type specific, it has been suggested that a vaccine based on gpl20 should contain a mixture of recombinant proteins representing selected sequences from the variable regions of different isolates (10) .
Protective immunity toward microorganisms is thought to be mediated by humoral and cellular mechanisms (11) . In the former, neutralizing antibodies may prevent the binding of the virus to its cellular receptor and subsequent internalization, or complement fixing antibodies may result in virolysis (12) . In the latter, cytotoxic T cells, recognizing viral antigens on the cell membrane in association with class I major histocompatibility complex antigens, lyse the infected cells (13) . Cytotoxic T cells require help from CD4 antigenpositive helper T cells, possibly by cell-to-cell contact and by mediator molecules, such as interleukin 2 or y interferon, secreted by activated helper T cells that have recognized viral antigens. Helper T-cell proliferation, therefore, shows T-cell specific epitopes on the antigen used for stimulation and indicates that these epitopes will be recognized by the immune system.
In the present work we describe HIV-specific helper T-cell proliferative responses and neutralizing antibodies in animals immunized with native or recombinant envelope proteins but show the lack of a cellular immune response in HIV-infected individuals.
MATERIALS AND METHODS
HIV Isolates. Three HIV isolates, HTLV-IIIB, HTLV-IIIMN, and HTLV-IIIRF (2) were cultured in H9 cells in RPMI 1640 medium and 10% (vol/vol) fetal calf serum. These viruses represent the broad spectrum of divergence seen between different HIV isolates (3, 4, 14) . For immunoblots and for T-cell assays, virus concentrated by a factor of 5000 was prepared from the culture supernatant by Frederick Cancer Research Facilities (Frederick, MD) or by Electronucleonics (Silver Spring, MD). All three preparations contained the envelope glycoproteins gp120 and gp4l, the polymerase proteins p53 and p64, and the core proteins p17, p24, and p55, specific for HIV (15) .
Immunogens. Native gpl20 was purified from HTLV-IIIBinfected H9 cells (2) by immunoaffinity chromatography and polyacrylamide gel electrophoresis, as described (8) . A deglycosylated form of gpl20 was obtained by treatment with endoglycosidase F, as described (9) . Recombinant proteins R10, PB1, and 590 ( Fig. 1) , representing the external (gpl20) and/or the transmembrane glycoprotein (gp4l) of HTLV-IIIB (8) were produced in Escherichia coli. R10 and 590 from lysed cells by pelleting the membrane fraction by centrifugation at 2000 x g, solubilizing the proteins in 8 M urea, and separating the proteins by ion-exchange and gel-filtration chromatography (10) . PB1 was purified as described (10) .
Immunization. Three rabbits were immunized with recombinant peptides R10, PB1, or 590. Two goats were immunized with PB1, and two goats were immunized with 590. Finally, three goats were immunized with native gpl20 and one with its deglycosylated form p58. The immunization schedule has been described (8) (9) (10) .
Abbreviations: HIV, human immunodeficiency virus; HTLV-III, human T-lymphotropic virus type III; LIF, leukocyte migration inhibitory factor.
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The publication costs of this article were defrayed in part by page charge payment. This article must therefore be hereby marked "advertisement" in accordance with 18 U.S.C. §1734 solely to indicate this fact. Immunoblots. The antibody specificity of the sera was tested on immunoblots (14) , using proteins from the concentrated HTLV-IIIB (Frederick Cancer Research Facilities) as antigen.
Neutralizing Antibody Assay. For assessment of neutralizing antibody activity of the sera, we used a helper T-cell line (ATH8) that is highly susceptible to the cytotoxic activity of HIV (16, 17) . The cell line carries the CD4 antigen that is characteristic of helper T cells and thought to be the receptor for HIV (18, 19) . The test sera were mixed in different dilutions with 100-500 tissue culture 50% infective dose units of HTLV-IIIB, HTLV-IIIMN, or HTLV-IIIRF, incubated for 60 min at room temperature, and added to 5 x 103 ATH8 cells, grown in 96-well microtiter plates. The cells were then cultured in RPMI 1640 medium with 10% (vol/vol) fetal calf serum and interleukin 2 at 10%, and fed at 3-day intervals. The cell viability was assessed after 10-14 days of culture by visual inspection. During this time the uninfected cultures had reached a cell density of 105 cells per well (see Fig. 3a ). In contrast, in cultures containing various amounts of virus and no neutralizing antibody, all cells were dead or only a few viable cells were left. Neutralizing titer was defined as the reciprocal of the serum dilution giving 80-100% protection against the cytolytic activity of the virus.
Cell-Mediated Immunity. Peripheral blood mononuclear cells were separated from heparinized blood by FicollHypaque gradient centrifugation, washed, and cultured in triplicate wells in RPMI 1640 and 10% (vol/vol) autologous plasma. Heat-killed whole HIV virions (560C for 30 min), native gpl20, or the recombinant peptides R10, PB1, or 590 were added to various cultures. Antigen concentrations were 50, 5, and 0.5 ug/ml for the whole virions; 5, 0.5, and 0.05 ,pg/ml for the recombinant peptides; or 1.0, 0.1, and 0.01 ,ug/ml for gpl20. The cultures were pulse-labeled with
[3H]thymidine (0.5 ,uCi per well; 1 Ci = 37 GBq) on day 5 and harvested on day 6. Incorporated [3H]thymidine was measured in a scintillation counter.
Leukocyte migration inhibitory factor (LIF) activity was assessed at day 5 as described (20) , using human polymorphonuclear cells as targets for migration inhibition. An inhibition of migration of 20% or more (LIF index, <80) has been shown to correlate to a positive cellular immune response (20) .
RESULTS
Immunoblots. Rabbits or goats immunized with either the native gpl20 or with the recombinant peptides R10 or PB1 recognized gpl20 in immunoblots (Fig. 2) . In addition, some of these animals produced antibodies that reacted with molecules (gp82/86 and gp47) that may represent fragments of the external envelope glycoprotein. Animals immunized with recombinant peptide 590 produced antibodies that reacted with the envelope fragment gp82/86 and faintly with the transmembrane glycoprotein gp4l.
Neutralizing Antibodies. In typical experiments (Fig. 3 ) serum with neutralizing antibodies could be easily distinguished from non-neutralizing serum. All four goat sera obtained by immunization with native gpl20 or p58 could neutralize HTLV-IIIB infection in vitro (Table 1) . However, no neutralization was observed with the other two HIV isolates, HTLV-IIIMN and HTLV-IIIRF. It is noteworthy that goat 508, immunized with a deglycosylated preparation of purified gpl20, also had neutralizing antibodies. In this respect our results with ATH8 assay are similar to those obtained earlier (10) with these same goat sera, but using the noncytolytic H9 cell as the target for HIV.
Neutralizing antibodies, although at lower titers, were also observed in the sera of rabbits and goats immunized with recombinant envelope proteins (Table 1) . Interestingly, although the rabbit sera against recombinant protein R10 showed high-titer antibodies to gpl20 in immunoblots, no neutralizing antibodies were observed. In contrast, seraagainst recombinant protein PB1 had type-specific neutralizing antibodies. Finally, sera against 590, recognizing the transmembrane glycoprotein gp4l, but not gpl20, had low-titer neutralizing activity against all three HIV isolates used (Table 1) .
Cell-Mediated Immunity. The results of T-cell proliferation assays are shown in Fig. 4 and presented in detail in Table 2 . All four goats immunized with the native gp120, showed a broad, group-specific T-cell proliferative response toward all three viral isolates tested. The group-specific nature of the reaction was further demonstrated by using purified gpl2O from two different isolates, one being the same and the other one different from the antigen used for immunization (Table  2) . It is worth noting that even goat 508, which was immunized with the deglycosylated envelope protein, had a groupspecific T-cell response. This response, however, took longer to appear and was demonstrable only after >6 months of immunization. In contrast, goats immunized with two recombinant peptides, PB1 and 590, although having neutralizing antibodies, did not show any T-cell proliferative response toward the viral isolates or the purified envelope glycopro- tReciprocal of serum dilution giving >80% protection for HTLV-III-induced cytolysis of ATH8 cells.
tPAGE-purified gpl20. §Deglycosylated gp120.
IIgpl2O purified with immunoaffinity column chromatography.
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Immunology: Krohn et al. (17) did not increase the T-cell responses (data not shown).
DISCUSSION
Analysis of the genomic structure of individual HIV isolates has demonstrated up to 30% variability. Because heterogeneity is greatest in the envelope glycoprotein (3), scepticism has been raised as to the future prospects for a HIV vaccine. The external HIV envelope glycoprotein gpl20, which theoretically would be the prime target for a protective immune response toward HIV, contains conserved and variable regions (3, 4) . Moreover, computer-assisted analysis predicted highly immunogenic epitopes within the variable and conserved regions of gpl20, as well as in the conserved sequences of the transmembrane envelope glycoprotein gp41 (14) . Programs to reveal sequences meeting the predicted criteria for T-cell epitopes (21) have also been used for the gpl20 molecule (22) . In our present work, neutralizing and non-neutralizing epitopes were demonstrated on gpl20. Antisera raised against the recombinant peptide R10, reacting strongly with gpl20 in immunoblots, had no neutralizing activity, whereas anti-PB1 had a relatively potent neutralizing effect. The strongest neutralization was seen, however, with the antisera against the native glycosylated envelope protein gpl20.
The demonstration of group-specific neutralizing activity in the rabbit and goat sera raised with recombinant peptide 590 is of interest, as this may be due to antibodies against gp4l. Earlier studies have indicated that gp4l in fact contains neutralizing epitopes (23), whereas antibodies against one immunogenic region, p121, were not neutralizing. gp4l has three hydrophobic regions (14) and may thus span the viral membrane more than once, forming external structures that could act as targets for neutralizing antibodies. In our work with sera from HIV-infected men (24) , neutralizing activity correlated better with antibody activity to gp4l than with activity toward gp120.
The present work shows that gpl20 carries also an immunogenic T-cell epitope, which will elicit a group-specific cellular immune response. The importance of glycosylation for this T-cell epitope is still unclear. No T-cell response toward gpl20 or toward the whole virion was seen in animals immunized with nonglycosylated recombinant proteins, suggesting that the sugar moieties are necessary for an immune response. Results with the deglycosylated native protein p58 are inconclusive, because the deglycosylation may have been incomplete resulting in an immunogen that contained some glycosylated species. Other alternative explanations for the lack of an HIV-targeted T-cell response in animals immunized with the recombinant peptides 590 or PB1 are differences in the folding of these env-derived proteins, interference by nonviral sequences at the ends of these proteins, and the possibility that the epitope is either located outside these peptides or is conformational, requiring the proper folding of extended regions, if not the entire envelope protein.
The nature of the T-cell-specific epitope(s) on gpl20 is unknown at present, but it may be related to the "fusion epitope," responsible for binding HIV to its target cell (18, 19) , which must also be group specific. Binding of gpl20 to CD4 requires proper glycosylation, as the deglycosylated molecule p58 shows only weak binding and the recombinant peptides R10 and PB1 do not bind at all to CD4 (9) . The gpl20   65  55  75  90  45  110  110  10  45  508  p58  20  35  45  80  35  60  45  5  40  517   gpl20   120  100  95  75  55  85  75  15  42  2935   gpl20   125  85  140  100   95   85  35  20  60  987  PB1  <2  <2  <2  <2  <2  5  150  <2  98  988  PB1  <2  <2  <2  <2  <2  1  10  <2  112  989  590  <2  <2  <2  <2  <2  1  1  <2  107  991  590  <2  <2  <2  <2  <2  10  50  <2  96  Control   -<2  <2  <2  <2  <2  <2  <2  <2  102 *Stimulation index = cpm of culture with antigen/cpm of culture without antigen.
tLIF index = (area of migration with antigen/area of migration without antigen) x 100.
Immunology: Krohn et A possibility that the fusion epitope on gpl20 is also the main T-cell epitope could explain the lack of T-cell response toward HIV in infected individuals, as observed in the present work and by others (25) . Based on blocking studies with monoclonal antibodies against different parts of CD4 (26), we have suggested (27) , that the gpl20 fusion site three-dimensionally mimics the nonpolymorphic region of the HLA class II molecule that normally binds to CD4. Thus the internal tolerance toward "self' structures would prevent the T-cell response, but not the B-cell response, toward a corresponding structure on gpl20. Another possible explanation is the general immune deficiency caused by the infection (28) or viral proteins that could suppress the in vitro response (29) (30) (31) . Our results (Table 3) demonstrate that no T-cell response toward the whole HIV virions was seen in the infected individuals even when their T-cell response toward other foreign antigens, such as tuberculin purified peptide derivative, was intact or only slightly decreased. Moreover, anergy was also observed when purified envelope glycoprotein gpl20 or recombinant envelope proteins were used as antigens. These data, therefore, argue against the general immunodeficiency or a suppressive viral protein being the cause for the anergy against HIV in man.
In summary, we have shown potent antigenic epitopes on the envelope glycoprotein of HIV, capable of inducing neutralizing antibodies and a T-cell-specific immune response in immunized animals. Whether the same epitopes are also immunogenic in man and whether they can induce a protective immune response toward subsequent exposure to HIV is a question that will require more direct experiments.
